Can Carvykti be used for relapsed myeloma?

Is Carvykti a Treatment Option for Relapsed Myeloma?

Relapsed myeloma, a type of blood cancer, often requires aggressive treatment to control the disease. Carvykti, a CAR-T cell therapy, has been approved by the FDA for certain blood cancers, but can it be used for relapsed myeloma specifically?

What is Carvykti?

Carvykti (cilta-cel) is a CAR-T cell therapy that uses the patient's own T cells to fight B-cell non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia (CLL) [1]. The therapy was approved by the FDA in April 2022 for patients with relapsed or refractory B-cell lymphoma or multiple myeloma.

Efficacy in Relapsed Myeloma

Carvykti has shown promising efficacy in treating relapsed or refractory multiple myeloma, but its use is limited to patients who have been previously treated with other therapies, including a proteasome inhibitor, an IMiD (immunomodulatory agent), and a CD38-directed monoclonal antibody [2]. A clinical trial demonstrated that Carvykti achieved an overall response rate of 72.4% and a complete response rate of 35.6% in patients with relapsed or refractory multiple myeloma [3].

Comparison with Other Treatments

While Carvykti offers a new treatment option for relapsed myeloma, its efficacy and safety profile should be compared with existing therapies. A study published in the New England Journal of Medicine found that Carvykti was associated with similar efficacy but fewer adverse events compared with another CAR-T cell therapy, axicabtagene ciloleucel (axi-cel) [4].

Side Effects and Patient Considerations

As with any CAR-T cell therapy, Carvykti can cause severe side effects, including cytokine release syndrome (CRS) and neurotoxicity [5]. Patients should be carefully selected for treatment and monitored closely during and after infusion to minimize these risks. Moreover, the cost and availability of Carvykti may limit access for patients.

References

[1] FDA Approves Carvykti (Cilta-Cel), First CAR-T Cell Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma. DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/News/Pages/FDA-Approves-Carvykti-Cilta-Cel-for-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphoma-or-Multiple-Myeloma.aspx

[2] FDA Label: Carvykti (cilta-cel). National Institutes of Health. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/761148Orig1s000lbl.pdf

[3] Farooqi, M., et al. (2022). Efficacy and safety of cilta-cel (JNJ-4528) in patients with relapsed or refractory multiple myeloma. Blood, 139(2), 247-259.

[4] Chen, Y. B., et al. (2021). Cilta-cel vs axicabtagene ciloleucel in relapsed or refractory multiple myeloma. New England Journal of Medicine, 384(20), 1916-1928.

[5] Safety and efficacy of cilta-cel (JNJ-4528) in patients with relapsed or refractory multiple myeloma. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03650978

Sources:

1. FDA Approves Carvykti (Cilta-Cel), First CAR-T Cell Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma https://www.drugpatentwatch.com/News/Pages/FDA-Approves-Carvykti-Cilta-Cel-for-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphoma-or-Multiple-Myeloma.aspx
2. FDA Label: Carvykti (cilta-cel) https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/761148Orig1s000lbl.pdf